Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FH-2001 plus serplulimab in advanced solid tumors
CTR20242660Phase 2Active
- Sponsor
- CSPC Xingsheng Xinhui Pharmaceutical
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of FH2001, serplulimab in hepatocellular carcinoma (HCC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, Nonhematologic neoplasms, sponsored by CSPC Xingsheng Xinhui Pharmaceutical. Started Nov 2024; status: active.
02
Drugs
FH2001serplulimab
03
Conditions
hepatocellular carcinoma (HCC)gastric adenocarcinomagastroesophageal junction adenocarcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242660.